CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2005
Friday November 4, 7:00 am ET
PALO ALTO, Calif., Nov. 4 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX - News) today announced that data from the Evaluation of Ranolazine In Chronic Angina (ERICA) study and two studies related to the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) will be presented at the American Heart Association (AHA) Scientific Sessions 2005. ASCOT evaluated an amplodipine plus or minus perindopril based treatment regimen compared to an atenolol plus or minus bendroflumethiazide based regimen. The AHA Scientific Sessions 2005 will take place in Dallas, TX from November 13-16, 2005. The presentations include:
-- Anti-Anginal Efficacy of Ranolazine When Added to Maximal Therapy with
Conventional Therapy: The Efficacy of Ranolazine in Chronic Angina
Trial. Wednesday, November 16, 2005 from 3:45 p.m. to 4:00 p.m. Central
Time (CT), Dallas Convention Center, C140. Oral abstract #3491.
-- Differential Impact of Blood Pressure-Lowering Drugs on Central
Arterial Pressure influences Clinical Outcomes - Principal Results of
the Conduit Artery Function Evaluation (CAFE) Study in ASCOT. Sunday,
November 13, 2005 from 3:45 p.m. to 4:00 p.m. CT, Dallas Convention
Center, Arena. Late Breaking Clinical Trial.
-- Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT
LLA) Revisited: Interaction of Antihypertensive and Lipid Lowering
Therapy. Monday, November 14, 2005 from 4:15 p.m. to 4:30 p.m. CT,
Dallas Convention Center, D220. Oral abstract #730.
Additional information regarding the AHA Scientific Sessions 2005 can be accessed at scientificsessions.org.
The ASCOT study was neither funded nor sponsored by CV Therapeutics, Inc.
About CV Therapeutics
CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.
CV Therapeutics currently has three programs in commercial or late-stage development: ACEON® (perindopril erbumine) Tablets, Ranexa(TM) (ranolazine) and regadenoson. CV Therapeutics also has other clinical and preclinical drug development candidates and programs. The company co-promotes ACEON®, an ACE inhibitor, for the treatment of essential hypertension and reduction of the risk of cardiovascular mortality or non-fatal myocardial infarction in patients with stable coronary artery disease. Ranexa is being developed as a novel potential treatment for chronic angina. Regadenoson is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies. Ranexa and regadenoson have not been approved for marketing by any regulatory authorities. |
